Trial Profile

Phase 1 Single Ascending Dose (SAD) study of AUR200

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 12 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AUR 200 (Primary)
Indications Autoimmune disorders
Focus Adverse reactions
Sponsors Aurinia Pharmaceuticals

Most Recent Events

27 Feb 2025 According to an Aurinia Pharmaceuticals media release, initial results from this Phase 1 study of AUR200 expected in the second quarter of 2025.
05 Sep 2024 Status changed from planning to recruiting.
05 Sep 2024 According to an Aurinia Pharmaceuticals media release,the first participant has been dosed in a Phase 1a single ascending dose (SAD) study of AUR200.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com